VISEN Pharmaceuticals
VISEN Pharmaceuticals Fundamental Analysis
VISEN Pharmaceuticals (2561.HK) shows moderate financial fundamentals with a PE ratio of -12.74, profit margin of 94.40%, and ROE of -26.24%. The company generates $-0.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 20.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 2561.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak2561.HK struggles to generate sufficient returns from assets.
Valuation Score
Moderate2561.HK shows balanced valuation metrics.
Growth Score
Weak2561.HK faces weak or negative growth trends.
Financial Health Score
Excellent2561.HK maintains a strong and stable balance sheet.
Profitability Score
Weak2561.HK struggles to sustain strong margins.
Key Financial Metrics
Is 2561.HK Expensive or Cheap?
P/E Ratio
2561.HK trades at -12.74 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 2561.HK's PEG of 2.01 indicates potential overvaluation.
Price to Book
The market values VISEN Pharmaceuticals at 2.54 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -19.85 times EBITDA. This is generally considered low.
How Well Does 2561.HK Make Money?
Net Profit Margin
For every $100 in sales, VISEN Pharmaceuticals keeps $94.40 as profit after all expenses.
Operating Margin
Core operations generate 89.63 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-26.24 in profit for every $100 of shareholder equity.
ROA
VISEN Pharmaceuticals generates $-19.12 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
VISEN Pharmaceuticals generates strong operating cash flow of $-160.41M, reflecting robust business health.
Free Cash Flow
VISEN Pharmaceuticals generates strong free cash flow of $-160.41M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $-1.47 in free cash annually.
FCF Yield
2561.HK converts -6.20% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-12.74
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
2.01
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.54
vs 25 benchmark
P/S Ratio
Price to sales ratio
-1311.07
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.001
vs 25 benchmark
Current Ratio
Current assets to current liabilities
22.99
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.26
vs 25 benchmark
ROA
Return on assets percentage
-0.19
vs 25 benchmark
ROCE
Return on capital employed
-0.19
vs 25 benchmark
How 2561.HK Stacks Against Its Sector Peers
| Metric | 2561.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -12.74 | 28.45 | Better (Cheaper) |
| ROE | -26.24% | 763.00% | Weak |
| Net Margin | 9439.86% | -45265.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 22.99 | 2795.60 | Strong Liquidity |
| ROA | -19.12% | -16588.00% (disorted) | Weak |
2561.HK outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews VISEN Pharmaceuticals's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation